FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

October 10, 2017: By Joan McKenna

SparkSpark Therapeutics’ gene therapy candidate for inherited retinal disease will be reviewed Oct. 12 by the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee.

The panel will consider whether to recommend voretigene neparvovec, branded Luxturna, for the treatment of patients with vision loss due to retinal dystrophy caused by flaws in the RPE65 gene.

Spark says the gene mutation breaks the visual cycle of light activating photoreceptors, resulting in progressive vision loss and often near blindness.

The FDA has granted orphan drug, breakthrough therapy, and rare pediatric disease designations for voretigene neparvovec, a one-time treatment.

Spark estimates that disease affects an estimated 1 thousand to 3 thousand patients in the US.

Philadelphia-based Spark, founded in March 2013, now has a workforce of 300 industry professionals and has secured $1 billion in financing. It has a pipeline of eight investigational gene therapies. Luxturna is its lead candidate.

The panel meeting will run 8:30 to 5 p.m. Oct. 12 at the FDA’s White Oak Campus in Silver Spring, Maryland.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023